How the US pharmaceutical industry is struggling to meet demand for lifesaving medicines
The US pharmaceutical and medical device industry is reeling from the recent wave of high-profile cases of drug resistance, which has led to the deaths of tens of thousands of people worldwide.
The pharmaceutical industry’s health costs have risen steadily as it struggles to keep up with a demand for drugs with less side effects and greater side effects than its competitors.
And, as the industry tries to figure out how to deal with this new reality, its stocks are struggling.
Gw Pharmaceuticals, maker of Zohydro and AstraZeneca, has seen its stock price tumble more than 20 percent since March, when it hit its lowest point of the year.
Its stock price has fallen from $20.90 to $14.70.
Janssen Pharmaceuticals and St. Jude Medical Corp., maker of ACEK and Lantus, have both dropped 20 percent, respectively, over the same time period.
St. Joseph’s, a biopharmaceutical company that focuses on immunotherapy, has lost almost half its value.
Gwynne-Meadow Pharmaceuticals has fallen 14 percent, while its stock has dropped more than 12 percent in the last three months.
As the industry struggles to deal, it has also been struggling to keep a lid on new and innovative drugs that have not been available in the U.S. since the early 1980s, when drug shortages became the norm in the country.GPs are increasingly becoming more patient-focused in terms of prescribing and the pace of their prescriptions, but a lack of data and research have left many doctors struggling to get their patients the drugs they need.
It is not just the drugs that are in short supply.
There are also an increasing number of patients who do not have the money to get them and who have been put on waiting lists.
In March, the Drug Enforcement Administration reported that 1.3 million prescriptions for medications had been written in the US in the past 12 months.
And that figure has increased each month since March.
Drug shortages have been a problem for years in the United States, but there is an even bigger problem with the supply of medicines.
While the U and European countries are trying to find new ways to keep their economies running, the U, and the EU in particular, are going after the pharmaceutical industry for not keeping up with the pace at which they need new medicines.
There are now at least two different ways that drug companies are able to make money: through patents, or by selling new drugs through a pharmacy chain.
In the U., companies can patent their medicines, which are not manufactured by manufacturers and are not controlled by the FDA.
The patent system gives the pharmaceutical companies the ability to make any new drugs that they want.
But the patent system also has the effect of encouraging companies to increase the prices of new drugs.
Patents also are not designed to keep drugs affordable, but instead to provide monopolies, in which a single company has exclusive rights to make the medicine for a certain patient population.
This has created a situation where if a drug becomes more popular than the existing market, it is priced higher than a competitor that has the same drug and is also able to manufacture it.
In this case, the price increases are not only for the generic versions of the drugs, but also for the brand-name versions.
The pharmaceutical companies can also sell generic versions to lower-income patients.
But it’s not enough for the drug companies to sell generic drugs.
In order to sell these cheaper drugs, they need to increase their profits by adding to the list of new medicines that they must offer.
The drug companies also have to raise the prices they charge for the older generic versions, which they cannot do.
To try to fix the problem, the pharmaceutical and health insurance companies have launched a series of initiatives aimed at improving the pricing of new medications, but they are also taking a step back.
The new policies do not address the underlying causes of the drug shortages and are likely to do more harm than good.
For instance, the Obama administration announced in March that it would require drug companies that are selling new generics to add the generic version of the medication to their list of approved medications.
This would mean that the generic would be cheaper than the brand.
But this requirement does not address a number of other problems: It will only cover the brand versions of drugs, which will still cost more than the branded version.
This is a problem because the generic does not have any safety data to compare the two.
The same cannot be said about the brand version, which is not considered as safe.
The price increase will only work if there is a large enough demand.
In the meantime, generic companies will continue to make less money.
And, in fact, there is not enough demand to make a difference, because the supply has remained largely unchanged.
The pharmaceutical industry has also